Acquired by Pfizer in March 2022
ARNA - Arena Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Park City,
United States
Type: Equity
ARNA price evolution
ARNA
| (in millions $) | 31 Dec 2021 | 30 Oct 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $224.57 | $386.65 | $514.18 | $432.98 |
| Short term investments | $325.9 | $385.01 | $457.36 | $655.85 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $569.47 | $790.92 | $990.43 | $1121.61 |
| Long term investments | $160.8 | $52.95 | $34.42 | |
| Property, plant & equipment | $19.13 | $19.56 | $20.39 | $21.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $215.24 | $110.11 | $94.22 | $62.33 |
| Total investments | $486.69 | $437.97 | $491.78 | $655.85 |
| Total assets | $784.71 | $901.03 | $1084.66 | $1183.94 |
| Current liabilities | ||||
| Accounts payable | $32.13 | $30.04 | $23.42 | $21.98 |
| Deferred revenue | ||||
| Short long term debt | $5.05 | $4.88 | $4.72 | $4.56 |
| Total current liabilities | $66.32 | $53.35 | $64.84 | $47.51 |
| Long term debt | $36.16 | $37.48 | $38.78 | $40.03 |
| Total noncurrent liabilities | $45.15 | $46.95 | $48.74 | $50.44 |
| Total debt | $41.21 | $42.37 | $43.5 | $44.59 |
| Total liabilities | $111.47 | $100.31 | $113.58 | $97.94 |
| Shareholders' equity | ||||
| Retained earnings | -$2124.16 | -$1968.56 | -$1772.24 | -$1626.15 |
| Other shareholder equity | -$0.28 | $0.12 | $0.09 | $0.2 |
| Total shareholder equity | $673.24 | $800.72 | $971.08 | $1085.99 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $224.57 | $219.54 | $243.27 | $161.04 |
| Short term investments | $325.9 | $884.5 | $496.29 | $284.59 |
| Net receivables | $1.65 | $5.09 | ||
| Inventory | ||||
| Total current assets | $569.47 | $1139.31 | $759.93 | $460.73 |
| Long term investments | $160.8 | $370.94 | $82.41 | |
| Property, plant & equipment | $19.13 | $22.09 | $25.13 | $23.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $215.24 | $51.41 | $414.19 | $226.18 |
| Total investments | $486.69 | $884.5 | $867.23 | $367.01 |
| Total assets | $784.71 | $1190.72 | $1174.12 | $686.9 |
| Current liabilities | ||||
| Accounts payable | $32.13 | $35.35 | $25.5 | $16.18 |
| Deferred revenue | ||||
| Short long term debt | $5.05 | $4.4 | $3.81 | $3.28 |
| Total current liabilities | $66.32 | $58.08 | $44.97 | $29.92 |
| Long term debt | $36.16 | $41.21 | $45.61 | $49.43 |
| Total noncurrent liabilities | $45.15 | $52.17 | $57.69 | $50.73 |
| Total debt | $41.21 | $45.61 | $49.43 | $52.71 |
| Total liabilities | $111.47 | $110.25 | $102.66 | $80.64 |
| Shareholders' equity | ||||
| Retained earnings | -$2124.16 | -$1507.73 | -$1103 | -$1500.55 |
| Other shareholder equity | -$0.28 | $0.7 | $1.3 | -$0.15 |
| Total shareholder equity | $673.24 | $1080.47 | $1071.46 | $606.26 |
| (in millions $) | 31 Dec 2021 | 30 Oct 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.05 | |||
| Cost of revenue | ||||
| Gross Profit | $0.05 | |||
| Operating activities | ||||
| Research & development | $110.34 | $112.45 | $102.53 | |
| Selling, general & administrative | $34.51 | $31.94 | $29.46 | |
| Total operating expenses | $153.48 | $194.49 | $144.39 | $131.99 |
| Operating income | -$153.43 | -$194.49 | -$144.39 | -$131.99 |
| Income from continuing operations | ||||
| EBIT | -$154.6 | -$145.04 | -$117.34 | |
| Income tax expense | ||||
| Interest expense | $1 | $1.03 | $1.05 | $1.07 |
| Net income | ||||
| Net income | -$155.61 | -$196.31 | -$146.09 | -$118.42 |
| Income (for common shares) | -$155.61 | -$146.09 | -$118.42 | |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.05 | $0.32 | $806.43 | $17.97 |
| Cost of revenue | ||||
| Gross Profit | $0.05 | $0.32 | $806.43 | $17.97 |
| Operating activities | ||||
| Research & development | $419.51 | $323.74 | $231.5 | $115.03 |
| Selling, general & administrative | $126.21 | $103.22 | $77.62 | $47.72 |
| Total operating expenses | $624.35 | $426.96 | $323.69 | $162.75 |
| Operating income | -$624.3 | -$426.64 | $482.75 | -$144.78 |
| Income from continuing operations | ||||
| EBIT | -$612.27 | -$400.21 | $512.68 | -$133.97 |
| Income tax expense | $110.33 | -$110.27 | ||
| Interest expense | $4.16 | $4.52 | $4.79 | $5.7 |
| Net income | ||||
| Net income | -$616.43 | -$404.73 | $397.56 | -$29.4 |
| Income (for common shares) | -$616.43 | -$404.73 | $397.56 | -$29.4 |
| (in millions $) | 31 Dec 2021 | 30 Oct 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Net income | -$155.61 | -$460.82 | -$146.09 | -$118.42 |
| Operating activities | ||||
| Depreciation | $0.95 | $0.97 | $0.97 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.27 | $17.79 | $17.02 | |
| Total cash flows from operations | -$120.5 | -$331.52 | -$93.84 | -$119.99 |
| Investing activities | ||||
| Capital expenditures | -$0.53 | -$0.2 | -$0.1 | |
| Investments | -$50.38 | $162.79 | $227.21 | |
| Total cash flows from investing | -$50.92 | $372.32 | $162.59 | $227.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.28 | $13.51 | $107.42 | |
| Net borrowings | -$1.16 | -$1.09 | -$1.03 | |
| Total cash flows from financing | $9.13 | $126.28 | $12.42 | $106.39 |
| Effect of exchange rate | $0.21 | $0.03 | $0.02 | -$0.08 |
| Change in cash and equivalents | -$162.08 | $167.11 | $81.2 | $213.43 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$616.43 | -$404.73 | $397.56 | -$29.4 |
| Operating activities | ||||
| Depreciation | $3.87 | $3.86 | $3.23 | $3.76 |
| Business acquisitions & disposals | -$70 | |||
| Stock-based compensation | $70.37 | $59.92 | $53.05 | $19.54 |
| Total cash flows from operations | -$452.02 | -$353.09 | $568.69 | -$132.21 |
| Investing activities | ||||
| Capital expenditures | -$0.99 | -$0.82 | -$4.82 | -$0.69 |
| Investments | $392.39 | -$19.58 | -$493.13 | -$253.97 |
| Total cash flows from investing | $321.4 | -$21.4 | -$496.95 | -$251.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $139.81 | $354.42 | $13.15 | $389.03 |
| Net borrowings | -$4.4 | -$3.81 | -$3.28 | -$4 |
| Total cash flows from financing | $135.41 | $350.61 | $9.87 | $385.03 |
| Effect of exchange rate | $0.24 | $0.16 | -$0.01 | $0.65 |
| Change in cash and equivalents | $5.03 | -$23.73 | $81.6 | $2.2 |
News
|
Merger Arbitrage Mondays - Google (GOOG) Acquires Cybersecurity Firm Mandiant (MNDT)
Benzinga
14 Mar 2022
|
|
Arena Pharmaceuticals Inc. Climbs To Annual-High Share Price
Benzinga
10 Mar 2022
|
|
Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?
Zacks via Yahoo Finance
9 Mar 2022
|
|
Arena Pharma gains after report Pfizer deal will clear without HSR second request
Seeking Alpha
7 Mar 2022
|
|
John Dorfman: Why I think George Soros is wrong about Rivian
Pittsburgh Tribune-Review
28 Feb 2022
|
|
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
Zacks via Yahoo Finance
24 Feb 2022
|
|
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical...
Benzinga
23 Feb 2022
|
|
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead...
Benzinga
20 Feb 2022
|
|
Deals Are Booming, but Antitrust Scrutiny Has Deal Traders Worried
The Wall Street Journal
12 Feb 2022
|
|
Despite High Forecasts for 202
Guru Focus
12 Feb 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$616.43M |
| Revenue Q/Q | 45.95% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -62.36% |
| ROE | -69.83% |
| Debt/Equity | 0.17 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.59 |
| Quick ratio | 8.59 |